SL-T10
/ SL VaxiGen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 03, 2024
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
(clinicaltrials.gov)
- P1 | N=78 | Recruiting | Sponsor: SL VAXiGEN
New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1